WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced a significant surge in demand for its lead product, YCANTH®, in the second quarter of 2025, reporting 13,434 dispensed applicator units. This figure marks a 32.8% increase over the first quarter of 2025, reflecting an acceleration in growth momentum compared to the previous quarter’s 16.7% sequential increase.
Jayson Rieger, PhD, MBA, President and CEO of Verrica, described the second-quarter performance as a clear validation of the company’s focused commercial strategy. “The substantial growth for YCANTH dispensed applicator units in the second quarter proves that our more focused commercial strategy is driving significant product demand, with a growing number of both dermatology and pediatric physician practices now prescribing YCANTH,” Rieger said. He noted that the expansion of patient access, strong reimbursement support, and an extensive distribution network are key factors enabling broader adoption among healthcare providers.
In addition to strong domestic performance, Verrica received an \$8 million milestone payment from its Japanese partner, Torii Pharmaceutical, for initiating a global Phase 3 program to study YCANTH in the treatment of common warts. This payment is part of a broader collaboration that includes additional potential milestones and financial support for clinical development.
Rieger emphasized that the company’s growth is underpinned by a combination of strategic execution and financial flexibility. Recent amendments to Verrica’s credit agreement with OrbiMed, alongside non-dilutive funding from Torii, are providing crucial support. Future milestones include a potential \$10 million payment upon regulatory approval of YCANTH in Japan for molluscum contagiosum, as well as Torii’s continued investment in global clinical studies.
Verrica also plans to update its development strategy for VP-315, a product candidate targeting basal cell carcinoma, signaling further pipeline advancement.
YCANTH® is the first FDA-approved treatment specifically for molluscum contagiosum, a highly contagious skin infection affecting an estimated six million Americans, primarily children. The drug-device combination uses a GMP-controlled cantharidin formulation in a single-use applicator, enabling precise topical dosing. Coverage for YCANTH extends to approximately 225 million insured lives in the U.S., with most commercially insured patients paying \$25 per treatment visit. Verrica also offers financial assistance to help reduce costs for uninsured patients.
The company’s robust second-quarter growth, coupled with strategic partnerships and ongoing pipeline development, positions Verrica to expand its market presence and deliver on its mission to address unmet dermatologic needs.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.